TR199801774T2 - 4-fenil-3, 6-dihidro-2H- piridil türevlerinin, NMDA reseptör alttip blokerleri olarak kullanimi. - Google Patents

4-fenil-3, 6-dihidro-2H- piridil türevlerinin, NMDA reseptör alttip blokerleri olarak kullanimi.

Info

Publication number
TR199801774T2
TR199801774T2 TR1998/01774T TR9801774T TR199801774T2 TR 199801774 T2 TR199801774 T2 TR 199801774T2 TR 1998/01774 T TR1998/01774 T TR 1998/01774T TR 9801774 T TR9801774 T TR 9801774T TR 199801774 T2 TR199801774 T2 TR 199801774T2
Authority
TR
Turkey
Prior art keywords
nmda receptor
receptor subtype
hydrogen
dihydro
phenyl
Prior art date
Application number
TR1998/01774T
Other languages
English (en)
Inventor
Bourson Anne
Fischer Gunther
Heitz Neidhart Marie-Paule
Mutel Vincent
Trube Gerhard
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR199801774T2 publication Critical patent/TR199801774T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut bulus, R1 in hidrojen, halojen, düsük moleküllü alkil veya düsük moleküllü alkoksi oldugu; R2 nin hidrojen oldugu; R3 ün hidrojen, amino, üreido, düsük moleküllü alkilkarbonil, düsük moleküllü alkilsülfonilamino, düsük moleküllü alkilkarbamoil, karbamoil, düsük moleküllü alkiloksikarbamoil, düsük moleküllü alkilamino veya R2 ve R3 beraberce alindiklarinda -(CH2)m- oldugu; Xin metilen, hidroksimetilen, düsük moleküllü alkoksimetilen veya karbonil oldugu; n' nin 1 veya 2 ve m' nin 3 veya 4 oldugu; genel formül (1)'in bilesiklerinin kullanimi ve yanisira NMDA reseptör alttipi spesifik blokerler için, terapötik endikasyonlari temsil eden hastaliklarin kontrolü veya tedavisi için ilaçlarin üretilmesi için, farmasötik olarak kabul edilebilir tuzlari ile ilgilidir.
TR1998/01774T 1996-03-08 1997-02-27 4-fenil-3, 6-dihidro-2H- piridil türevlerinin, NMDA reseptör alttip blokerleri olarak kullanimi. TR199801774T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96103636 1996-03-08

Publications (1)

Publication Number Publication Date
TR199801774T2 true TR199801774T2 (tr) 1998-12-21

Family

ID=8222541

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/01774T TR199801774T2 (tr) 1996-03-08 1997-02-27 4-fenil-3, 6-dihidro-2H- piridil türevlerinin, NMDA reseptör alttip blokerleri olarak kullanimi.

Country Status (15)

Country Link
US (1) US5962472A (tr)
EP (1) EP0885004B1 (tr)
JP (1) JP3248917B2 (tr)
KR (1) KR100352358B1 (tr)
CN (1) CN1131031C (tr)
AT (1) ATE216883T1 (tr)
AU (1) AU717140B2 (tr)
BR (1) BR9708171A (tr)
CA (1) CA2248134A1 (tr)
DE (1) DE69712325T2 (tr)
DK (1) DK0885004T3 (tr)
ES (1) ES2174220T3 (tr)
PT (1) PT885004E (tr)
TR (1) TR199801774T2 (tr)
WO (1) WO1997032581A1 (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
US6951875B2 (en) 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
EP2170334B1 (en) 2007-06-29 2021-03-17 Emory University Nmda receptor antagonists for neuroprotection
KR20100135847A (ko) * 2008-03-27 2010-12-27 에보텍 뉴로사이언시즈 게엠베하 Ｎｍｄａ ｎｒ２ｂ―서브타입 선택적 길항제를 사용한 질병 치료 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507239A (de) * 1968-12-24 1971-05-15 Hoffmann La Roche Verfahren zur Herstellung von aromatischen Äthern
CH558354A (de) * 1970-06-17 1975-01-31 Hoffmann La Roche Verfahren zur herstellung von aromatischen aethern.
US3879405A (en) * 1970-06-19 1975-04-22 Hoffmann La Roche Tetrahydropyridine derivatives
CH547802A (de) * 1970-06-19 1974-04-11 Hoffmann La Roche Verfahren zur herstellung von tetrahydropyridinderivaten.
US5149817A (en) * 1990-03-05 1992-09-22 Shionogi & Co., Ltd. Teirahydropyridine derivatives
DE4325855A1 (de) * 1993-08-02 1995-02-09 Boehringer Ingelheim Kg Neue Benzoesäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4325885A1 (de) * 1993-08-02 1995-02-09 Basf Ag Elektrolumineszierende Anordnung
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives

Also Published As

Publication number Publication date
KR19990087505A (ko) 1999-12-27
DK0885004T3 (da) 2002-08-19
PT885004E (pt) 2002-08-30
EP0885004B1 (en) 2002-05-02
BR9708171A (pt) 1999-07-27
EP0885004A1 (en) 1998-12-23
JP3248917B2 (ja) 2002-01-21
ATE216883T1 (de) 2002-05-15
DE69712325D1 (de) 2002-06-06
ES2174220T3 (es) 2002-11-01
CN1213304A (zh) 1999-04-07
AU1878297A (en) 1997-09-22
JP2000507542A (ja) 2000-06-20
CN1131031C (zh) 2003-12-17
DE69712325T2 (de) 2002-11-28
WO1997032581A1 (en) 1997-09-12
KR100352358B1 (ko) 2003-03-10
AU717140B2 (en) 2000-03-16
CA2248134A1 (en) 1997-09-12
US5962472A (en) 1999-10-05

Similar Documents

Publication Publication Date Title
BR9812046A (pt) Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto
ES2141137T3 (es) Agentes terapeuticos para la enfermedad de parkinson.
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
NO954694L (no) Doseringsform for antidepressiva
MY118163A (en) Aryl fused azapolycyclic compounds
MY117896A (en) Quinazoline derivatives
DK0533280T3 (da) Ny medicinsk anvendelse af tachykininantagonister
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
JO2321B1 (en) 4-phenyl-pyridine derivatives
WO1999024022A3 (en) Isoquinoline derivatives for treating disorders associated with 5ht7 receptors
FR2712591B1 (fr) Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
DK0779284T3 (da) Hidtil ukendte 2-naphtanamidderivater og terapeutiske anvendelser heraf som agonister af D3-receptorer
NO20001514L (no) Vitronectin-reseptor-antagonist
HUP0104963A2 (hu) Bőrbetegségek kezelésére szolgáló készítmények
TR199801774T2 (tr) 4-fenil-3, 6-dihidro-2H- piridil türevlerinin, NMDA reseptör alttip blokerleri olarak kullanimi.
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
NO961404L (no) 4-indolylpiperazinyl-derivater
SE9603285D0 (sv) New compounds
NO950177L (no) Farmakologisk aktive erivater
SE9401087D0 (sv) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
YU61096A (sh) Novi intermedijari, njihova primena u sintezi n,n'-premoštenih bisindolilmaleimida i farmaceutske formulacije
MY133438A (en) Morpholinobenzamide salts
NO973242L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av idiopatisk eller fysiologisk gynekomasti
NO992316L (no) Benzensulfonamidderivater og legemidler inneholdende disse
DK1082116T3 (da) Anvendelse af 4-piperidinmethanolderivater til behandling af neurologiske sygdomme